Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intranasal Oxytocin in Hypothalamic Obesity

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT02849743
Recruitment Status : Recruiting
First Posted : July 29, 2016
Last Update Posted : October 14, 2019
Sponsor:
Information provided by (Responsible Party):
Shana McCormack, MD, Children's Hospital of Philadelphia

Brief Summary:
This research study will test if oxytocin, delivered by nasal spray, will promote weight loss in children, adolescents, and adults with Hypothalamic Obesity as compared to a placebo. The study is divided into two parts. During the first part, subjects will receive either oxytocin or placebo. In the second part, subjects will "cross-over" to receive the other treatment - either oxytocin or placebo. During study visits participants will do blood tests, physical exams, metabolic testing, a MRI scan, and some surveys and questionnaires.

Condition or disease Intervention/treatment Phase
Craniopharyngioma Hypothalamic Obesity Drug: Syntocinon Drug: Placebo (for Syntocinon) Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Intranasal Oxytocin to Promote Weight Loss in Children, Adolescents, and Adults With Brain Tumors and Hypothalamic Obesity Syndrome
Study Start Date : October 2016
Estimated Primary Completion Date : June 2020
Estimated Study Completion Date : June 2021


Arm Intervention/treatment
Experimental: Syntocinon (= Oxytocin), then Placebo
  1. Intranasal oxytocin, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)
  2. Intranasal placebo, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks) *Dose Escalation, as appropriate, at 2 Weeks
Drug: Syntocinon
The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.

Drug: Placebo (for Syntocinon)
The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.

Experimental: Placebo, then Syntocinon (= Oxytocin)
  1. Intranasal placebo, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)
  2. Intranasal oxytocin, administered 3 times per day (at mealtimes) for 8 weeks (dosage based on weight: 16 IU to 24 IU; dose escalation, if appropriate, occurs at 2 weeks)
Drug: Syntocinon
The active substance of Syntocinon is a synthetic nonapeptide identical to the posterior pituitary hormone oxytocin.

Drug: Placebo (for Syntocinon)
The placebo is identical to the Syntocinon formulation with the exception of the active compound, i.e., without oxytocin.




Primary Outcome Measures :
  1. Weight loss [ Time Frame: 8 weeks ]
    The primary objective of this study is to determine whether treatment with 8 weeks of inhaled OXT (relative to 8 weeks of placebo) will promote weight loss in children and adolescents with brain tumors and hypothalamic obesity syndrome ages 10 to 21 years. Specifically, the primary outcome will be: the difference of the post-treatment weight between the two periods (treatment vs. placebo); the statistical model will include the difference of the baseline weight between the two periods and the sequence (OXT-PBO versus PBO-OXT).


Secondary Outcome Measures :
  1. Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 [ Time Frame: Assessed during each treatment block: at weeks 0 & 12, 0.3 & 12.3, 2 & 14, 2.3 & 14.3, 6 & 18, 8 & 20 and any unscheduled visits ]
    All subjects receiving at least one dose of OXT and/or placebo will be included in the safety analysis. The frequencies of AEs by type, body system, severity and relationship to study drug will be summarized. SAEs (if any) will be described in detail. In particular, the proportion of study subjects who were able to achieve the full dosing amount and the proportion of those receiving synthetic vasopressin requiring modification to their usual synthetic vasopressin regimen will also be noted. The incidence of hyponatremia will be reported. Participants will be screened for adverse events using a safety monitoring uniform report form (SMURF).

  2. Peripheral oxytocin area under the curve (AUC) [ Time Frame: Assessed during each treatment block: at either initial dose at baseline (week 0 & week 12) or increased dose at 2 weeks (week 2 & week 15); 50% of participants at each set ]
    We will determine the immediate peripheral pharmacokinetics of intranasal oxytocin (versus placebo/endogenous oxytocin).


Other Outcome Measures:
  1. Cognitive restraint at test meal [ Time Frame: Assessed during each treatment block: at either initial dose at baseline (week 0 & week 12) or increased dose at 2 weeks (week 2 & week 15); 50% of participants at each set ]
    Measured using stop-signal task

  2. Calories consumed at test meal [ Time Frame: Assessed during each treatment block: at either initial dose at baseline (week 0 & week 12) or increased dose at 2 weeks (week 2 & week 15); 50% of participants at each set ]
    Measured using standardized meal

  3. Resting energy expenditure (kcal/kg lean body mass/day) [ Time Frame: Assessed at the end of each treatment block: week 8 & week 20 ]
    Measured using indirect calorimetry

  4. Respiratory quotient (VCO2/VO2) [ Time Frame: Assessed at the end of each treatment block: week 8 & week 20 ]
    Measured using indirect calorimetry

  5. % body fat [ Time Frame: Assessed at the end of each treatment block: week 8 & week 20 ]
    Measured using dual energy x-ray absorptiometry

  6. Skeletal muscle oxidative phosphorylation capacity [ Time Frame: Assessed at the end of each treatment block: week 8 &week 20 ]
    Measured using MRI-based post-exercise Creatine Chemical Exchange Saturation Transfer (CrCEST) decline exponential time constant

  7. Hyperphagia [ Time Frame: Assessed during each treatment block: at screening, week 2 & week 14 (dose escalation), week 4 & week 16 (interim visit), and week 8 & week 20 (final visit) ]
    Measured using the Hyperphagia Questionnaire

  8. Disinhibition of eating [ Time Frame: Assessed during each treatment block: at screening, week 2 & week 14 (dose escalation), week 4 & week 16 (interim visit), and week 8 & week 20 (final visit) ]
    Measured using the Eating Inventory questionnaire

  9. Mental and emotional health related quality of life [ Time Frame: Assessed during each treatment block: at screening, week 2 & week 14 (dose escalation), week 4 & week 16 (interim visit), and week 8 & week 20 (final visit) ]
    Measured using the National Institute of Neurological Disorders and Stroke (NINDS) quality of life in neurological disorders (Neuro-QoL) scale

  10. Family function [ Time Frame: Assessed during each treatment block: at screening, week 2 & week 14 (dose escalation), week 4 & week 16 (interim visit), and week 8 & week 20 (final visit) ]
    Measured using the Family Assessment Device-General Function Scale (FAD-GRS)

  11. Voluntary physical activity [ Time Frame: Assessed during each treatment block: at screening, week 2 & week 14 (dose escalation), week 4 & week 16 (interim visit), and week 8 & week 20 (final visit) ]
    Measured using the Bone Mineral Density in Childhood Study (BMDCS) physical activity questionnaire

  12. Eye-tracking task [ Time Frame: Assessed at the end of each treatment block: week 8 & week 20 ]
    Amount of time spent viewing socially relevant versus socially irrelevant stimuli during eye-tracking

  13. EEG task [ Time Frame: Assessed at the end of each treatment block: week 8 & week 20 ]
    N170 EEG signal during eye-tracking



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   10 Years to 35 Years   (Child, Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  1. Proficient in English.
  2. Males or females age 10 to 35 years, inclusive.
  3. Weight ≥ 51 kg.
  4. Girls must have a negative urine/serum pregnancy test and post-menarchal girls must use an acceptable method of contraception, including abstinence, a barrier method (diaphragm or condom), Depo-Provera, or an oral contraceptive, for the duration of the study.
  5. Hypothalamic obesity, defined for the purposes of this protocol as:

    • previously diagnosed with a brain tumor*
    • currently overweight or obese (BMI > 85%ile for age/sex for < 18 years, BMI > 25 kg/m2 for 18 - 21 years)
    • has at least one other endocrinopathy, indicating hypothalamic damage
    • rate of annualized weight gain during any 6 month period (given variability in clinical course) preceding or after diagnosis and treatment greater than 2 standard deviations above population reference ranges for age and sex.
  6. At least 6 months since completion of therapy with stable disease/lack of recurrence.
  7. Stable for at least 2 months on any pituitary replacement (e.g., glucocorticoid, thyroid hormone, estrogen/progestin or testosterone, growth hormone, except for adjustments of less than or equal to 20%). (Desmopressin is not required to be stable for 2 months. Participants with DI taking desmopressin are required to have intact thirst and be well-controlled on their current dosing regimen.)
  8. Stable for at least 2 months on any appetite-modulating medications (e.g., stimulants).
  9. Be able to ambulate independently.
  10. Parental/guardian permission (informed consent) and child assent.

Exclusion Criteria:

  1. Diabetes insipidus without intact thirst mechanism (i.e., history that participant is not thirsty when hypernatremic and/or continues to be thirsty when hyponatremic, by participant/family and/or practitioner report and medical records) and/or "brittle" diabetes insipidus, defined as requiring >1 admission in the past year and/or any admission within the previous 3 months.
  2. Diabetes mellitus requiring insulin or insulin secretagogue. Laboratory values: HgbA1c ≥8%
  3. Cardiovascular condition, as defined as any of the following: i) abnormal blood pressure, defined as <3%ile or >97%ile for age, sex and height; ii) history of cardiac arrhythmia or arrhythmia detected on screening ECG; iii) history of heart failure and/or cardiomyopathy; iv) prolonged QTc interval (QTc > 460 msec), and/or long QT syndrome phenotype and/or positive genotype for long QT syndrome pathogenic mutations.
  4. Concurrent use of medications known to prolong QTc interval and pose high risk for Torsades de Pointes (TdP) according to the current information available (www.crediblemeds.org). Concomitant medications will be assessed by IDS pharmacist, in collaboration with study cardiologist, if additional clarification is needed. In addition, we require that potential participants be on a stable dose for at least 2 months of any medication with the potential to alter cardiac rhythm to ensure the screening ECG reflects steady-state physiology.
  5. History of liver disease, with screening laboratory studies:

    Laboratory values: ALT/SGPT > 3.0X upper limit of normal or AST/SGOT > 3.0X upper limit of normal

  6. History of chronic kidney disease, with screening laboratory studies:

    Laboratory values: eGFR < 60 mL/min/1.73m2, as defined by the Schwartz formula

  7. Clinically significant anemia, with screening laboratory studies:

    Laboratory values: Hemoglobin < 10 g/dL

  8. Seizure in the past 12 months.
  9. History of gastrectomy, gastric bypass, small or large bowel resection.
  10. History of active substance abuse.
  11. Current psychotic disorder and/or suicidality.
  12. Supra-physiologic (>15 mg/m2/day) prescribed doses of hydrocortisone equivalent.
  13. Anticipated clinical plan to initiate or modify pituitary hormone replacement and/or appetite-modulating drugs during the course of the study.
  14. Any investigational drug use within 30 days prior to enrollment.
  15. Pregnant or lactating females.
  16. Individuals with a known sensitivity to either oxytocin or the components of its formulation.
  17. Inability to take an intranasal medication (e.g., recent injury).
  18. Parents/guardians or subjects who, in the opinion of the Investigator, may be non-compliant with study schedules or procedures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02849743


Contacts
Layout table for location contacts
Contact: Kristin L Wade, MLitt (267) 426 - 8724 wadekl@email.chop.edu

Locations
Layout table for location information
United States, Pennsylvania
Children's Hospital of Philadelphia Recruiting
Philadelphia, Pennsylvania, United States, 19104
Contact: Krisin L Wade, M.Litt.    267-426-8724    wadekl@email.chop.edu   
Sponsors and Collaborators
Shana McCormack, MD
Investigators
Layout table for investigator information
Principal Investigator: Shana E McCormack, MD Children's Hospital of Philadelphia

Layout table for additonal information
Responsible Party: Shana McCormack, MD, Attending Physician, Children's Hospital of Philadelphia
ClinicalTrials.gov Identifier: NCT02849743     History of Changes
Other Study ID Numbers: 16-012730
First Posted: July 29, 2016    Key Record Dates
Last Update Posted: October 14, 2019
Last Verified: October 2019
Keywords provided by Shana McCormack, MD, Children's Hospital of Philadelphia:
oxytocin
hypothalamic obesity
craniopharyngioma
metabolism
Additional relevant MeSH terms:
Layout table for MeSH terms
Craniopharyngioma
Adamantinoma
Obesity
Overnutrition
Nutrition Disorders
Overweight
Body Weight
Signs and Symptoms
Neuroectodermal Tumors
Neoplasms, Germ Cell and Embryonal
Neoplasms by Histologic Type
Neoplasms
Neoplasms, Nerve Tissue
Bone Neoplasms
Neoplasms by Site
Bone Diseases
Musculoskeletal Diseases
Oxytocin
Oxytocics
Reproductive Control Agents
Physiological Effects of Drugs